Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Lilly and Hims & Hers expand access to FDA-approved Lilly medicines

6 November 2026 · By · Wire by Fusion42

Published

6 November 2026

Topic

opportunities

◆ Sectors

Digital Health

◆ Geography

United States

◆ Source

Read at businesswire.com →

◆ Verified

Fusion42 · 6 November 2026 · Fusion42 review

Eli Lilly and Hims & Hers have partnered to provide patients with easier access to FDA-approved Lilly obesity medicines, Zepbound and Foundayo, through Hims & Hers' telehealth platform at self-pay prices.

This Wire brief sits within Fusion42's coverage of Digital Health, and 5 sources have reported it between 6 Nov 2026 and 8 Nov 2026.

◆ ◆ The Wire takeaway

You now have a direct route to sell prescribed obesity drugs through Hims & Hers, bypassing traditional pharmacy chains and reaching patients digitally. This changes how obesity treatment is delivered and where to focus outreach this week.

◆ Coverage

5 sources · first reported 6 Nov 2026 · latest 8 Nov 2026

◆ Related on Wire

◆ Topics

Digital Healthtelehealthobesity-medicinesdigital-healthdirect-to-patientFDA-approved